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Conference Proceedings: Select Abstracts Presented at
2021 Advocate Aurora Health Scientific Day
Abstracts published within this supplement were presented at the 47th annual Advocate Aurora
Health Scientific Day, held virtually on May 26, 2021. This research symposium provides a
forum for disseminating results from studies conducted by faculty, fellows, residents, and
other allied health professionals associated with Midwest-based health system Advocate
Aurora Health, which publishes the Journal of Patient-Centered Research and Reviews.
ORAL PRESENTATIONS

Clinical Outcomes of Critically Ill Patients With COVID-19:
A Single-Center Cohort Study
Kenneth W. Dodd, Esmael Mayar, Brianna Miner, Gisele
Papo, Nathan Schoenrade, Paige Bird, David Barounis,
Katharine Burns, Nicholas Goodmanson, Varsha P. Gharpure
Emergency Medicine, Advocate Christ Medical Center;
Internal Medicine, Advocate Christ Medical Center; Advocate
Children's Hospital
Background: A global pandemic due to COVID-19 was declared
in March 2020. Cook County, Illinois, was an early epicenter of
the outbreak. Severe COVID-19 may result in respiratory failure
requiring mechanical ventilation or multisystem organ failure
requiring various organ support therapies.
Purpose: To describe the outcomes of critically ill patients with
COVID-19.
Methods: This prospective cohort study analyzed adult patients
admitted to Advocate Christ Medical Center (Oak Lawn, IL)
between March 1, 2020, and May 1, 2020, who were treated in a
medical intensive care unit for laboratory-confirmed COVID-19.
Primary outcome was in-hospital mortality. Secondary outcomes
were discharge location and length of stay. Results are stratified
by age and need for organ support (mechanical ventilation, renal
replacement therapy, and extracorporeal membrane oxygenation
[ECMO]). The primary analysis is descriptive in nature.
Results: In total, 218 patients were admitted during the study
period. Mean (standard deviation) age was 65.2 (13.4) years; 129
patients (59.2% were male, 91 (42%) were White, 82 (38%) were
Black, and 34 (16%) were Hispanic. Incidence of organ support
modalities included 79 (36%) mechanical ventilation, 34 (16%) renal
replacement therapy, and 2 (1%) ECMO. Overall in-hospital mortality
was 29% (n=80). For patients requiring organ support, mortality was
33 of 79 (42%) for mechanical ventilation, 25 of 34 (75%) for renal
replacement therapy, and 2 of 6 (33%) for ECMO. Rates of discharge
home were 63 of 125 (50%) for patients who did not require organ
support therapies, 24 of 79 (30%) for mechanical ventilation, 3 of
34 (9%) for renal replacement therapy, and 2 of 6 (33%) for ECMO.
For patients requiring mechanical ventilation, median (interquartile
range) hospital length of stay was 17.3 (11.3–27.5) days. In patients
older than age 74 who required mechanical ventilation, in-hospital
mortality was 11 of 16 (69%) and 0% were discharged to home.
Conclusion: Need for organ support modalities and increasing age
were associated with higher mortality and lower rate of discharge
to home during the early experience with COVID-19 at Advocate
Christ Medical Center. This study provides important baseline data
for clinical planning and future research.
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Detecting Cardiac Disease Using Artificial Intelligence
With 12-Lead Electrocardiographic Data
Christopher R. Beal, M. Fuad Jan, Arshad Jahangir, A. Jamil Tajik
Advocate Aurora Research Institute; Aurora Cardiovascular
Services, Aurora St. Luke’s Medical Center
Background: Cardiac diseases such as hypertrophic
cardiomyopathy (HCM) and aortic valve stenosis (AVS) affect the
heart’s main blood-pumping chambers and can result in adverse
outcomes like sudden cardiac death. The echocardiogram is the
gold standard to diagnose these diseases. Equipment and expertise
to perform this procedure can be costly in some health systems;
12-lead electrocardiograms (ECG) are lower-cost tools to establish
baseline cardiac function. However, these diseases present similarly
on ECGs, and distinguishing them is a clinical challenge.
Purpose: To confirm similar disease presentation, to detect disease
presence, and to identify features most indicative to detect disease,
using artificial intelligence.
Methods: A total of 16,781 ECGs were processed from 1461 adult
patients diagnosed with one disease after undergoing a previous
echocardiogram. A multiclass study design was used to detect disease
presence; 912 features were extracted from raw ECG signals in the
MUSE database. Training data consisted of 75% of the observations
(n=1096), and testing data consisted of the remaining 25% of the
observations (n=365). Feature selection with the SelectKBest method
reduced 912 features to a subset of 50 important features. Principal
component analysis was used to visualize how each disease presented
from the others. Multilayer perceptron and linear discriminant
analysis models classified diseases and were compared in terms of
accuracy, positive predictive value, and area under the curve.
Results: Principal component analysis showed one overlapping cluster
of 6 diseases, indicating data patterns for each disease are not wellseparated and confirming the challenge of separating scans. Multilayer
perceptron most accurately detected Fabry’s disease (83.6%); linear
discriminant analysis most accurately detected amyloidosis (75.4%).
From the 50 important features, feature values and lead numbers
characterized the diseases. S-wave features characterized amyloidosis,
HCM, and AVS (21, 17, and 17 occurrences, respectively); T-wave
features characterized Fabry’s disease (14 occurrences); R-wave
features characterized left ventricular hypertrophy and sarcoidosis
(13 occurrences). Lead V6 characterized amyloidosis, AVS, HCM,
and sarcoidosis (8, 11, 9, and 8 occurrences, respectively); Lead I
characterized left ventricular hypertrophy (8 occurrences); Lead III
characterized Fabry’s disease (13 occurrences).
Conclusion: The choice of classification model depends on the
chosen disease, and artificial intelligence is a useful tool in clinical
practice in conjunction with physicians’ trained expertise.
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Zika Virus Demonstrates Oncolytic Activity in a PatientDerived Glioblastoma Xenograft Model in Mice

Treatment Outcomes and Program Transition Rates
Across Substance Use Treatment Programs

Parvez Akhtar, Sam D. Zwernik, Deborah L. Donohoe,
Dmitry Bosenko, Catherine Warner, Richard A. Rovin

Mindy R. Waite, Kayla Heslin, Jonathan Cook, Michelle
Simpson

Advocate Aurora Research Institute; Neurosurgery, Aurora
Neurosciences Innovation Institute

Aurora Behavioral Health Services, Advocate Aurora
Research Institute; Aurora UW Medical Group; Center for
Urban Population Health; Ed Howe Center for Research,
Aurora Sinai Medical Center

Background: Glioblastoma is a malignant primary brain cancer.
The poor median survival rate of 15 months for patients with
glioblastoma has not budged in the past 15 years, when the current
standard treatment was first approved. There is no standard-ofcare chemotherapy for recurrent glioblastoma. We hypothesized
that Zika virus (ZIKV) can be purposed as an oncolytic virus for
glioblastoma. In order to test this hypothesis, we have used patientderived xenograft mouse model and investigated the oncolytic
potential of ZIKV.
Purpose: Preliminary in vitro data from our lab confirms that ZIKV
has tropism for commercial and patient-derived glioblastoma cell
lines through the AXL receptor, and the subsequent productive
infection is cytotoxic. Given this information, we wanted to
determine if ZIKV can work as an oncolytic virus against
glioblastoma in mouse models.
Methods: All procedures were approved by the Institutional
Animal Care and Use Committee. We used 6–8-week-old Fox
N1 Nude homozygous female mice. There were 4 experimental
arms: 2 patient-derived cell lines, each with a ZIKV-treated group
and a control group. The number of animals per experimental
arm was 12. Animals received subcutaneous flank injections of
patient-derived glioblastoma 8049 or 8049 AXLKO cells (2×106)
in 100 μl matrigel under isoflurane anesthesia. Animals were
observed daily, and weights and tumor measures were done 3
times per week. When tumor size reached 150 mm3, mice received
intratumoral injection of 2.5×106 ZIKV particles; control group
received intratumoral saline. At euthanasia, tissues were harvested
for immunohistochemistry and qRT-PCR was used to determine
ZIKV distribution.
Results: After 2–4 weeks of viral particle administration, striking
results were observed. ZIKV induced complete tumor remission in
22 of 24 animals (8049: 11 of 12; 8049 AXLKO: 11 of 12). There
was no tumor remission in 8049 and 8049 AXLKO control animals.
Overall survival of 8049 and 8049 AXLKO tumor-bearing mice
was significantly improved (P=0.001) by ZIKV treatment: median
survival of ZIKV-treated animals was 124 days for 8049 and 125
days for 8049 AXLKO, which compared to 42 days for 8049 and
46 days for 8049 AXLKO in control animals. Among ZIKV-treated
mice, there were 2 recurrences — 1 in the 8049 tumor (24 days
after significant tumor remission) and 1 8049 AXLKO tumor (7
days after significant tumor remission). We found a significant
amount of virus particles in ZIKV-infected tumors using qRTPCR. Histologic analysis confirmed necrotic tumor foci and ZIKVpositive tumor cells in treated animals.
Conclusion: ZIKV could be a potential oncolytic agent for
glioblastoma therapy.
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Background: Patients with substance use disorder represent a
diverse group of individuals with unique histories, demographics,
substance use patterns, and treatment-related behaviors. As a
result, several levels of treatment programs exist, including
inpatient, residential, partial hospitalization (PHP), intensive
outpatient (IOP), and outpatient. Program level is based on current
clinical needs, and best practice is to successfully complete a
program and transition to the next in a step-down manner. In
contrast, patients who discharge against medical advice, have
lower lengths of stay, or fail to transition are thought to have
worse outcomes. However, actual patient behaviors and their
outcomes within and across substance use treatment programs
are not well understood.
Purpose: To describe the outcomes and transition rates of patients
across substance use treatment programs.
Methods: Medical records were used to collect data from substance
use disorder treatment programs at a Midwest-based psychiatric
hospital between January 1, 2017, and December 31, 2019. Data
included treatment history, reason for discharge, admissions,
latency to program transitions, and location. Basic descriptive and
comparative statistics were conducted.
Results: Programs differed in rates of discharge against medical
advice. PHP had the highest rate of discharge against medical
advice, whereas residential treatment had the lowest. In most
programs, patients who discharged against medical advice had
similar rates of successful program transitions compared to
those who completed the program. Inpatients had higher rates of
6-month readmissions than any other treatment program. Whereas
lower acuity treatment programs (residential, PHP, IOP) had
decreased inpatient readmissions following program discharge,
inpatients had higher inpatient admission rates postdischarge
compared to before admission. Consistent with this, programs
had unique transition patterns, where inpatients were most likely
to readmit as inpatients, residential patients were most likely
to step down to PHP, PHP patients typically stepped down to
IOP, and IOP discharges transitioned across several programs.
However, a large subset of patients did not successfully transition
to any program. Insurance type was a factor in transitioning to
residential treatment.
Conclusion: Treatment-related behaviors and outcomes of patients
were unique across programs, potentially reflecting differences
in treatment intensities and patient acuities. Results highlight
opportunities for reducing readmissions and increasing successful
transitions.
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Anticoagulation for COVID-19–Associated Coagulopathy:
Experience of a Single Community Hospital

Effects of Therapeutic Anticoagulation for SARS-CoV-2
Coagulopathy on Markers of Inflammation and Mortality

Dana Mueller, Tyler Cooper, Lauren Sesemann, Lyndsey
Turbow, Nancy Guirguis, Marc McDowell, Poorvi Shah,
Bassem Chaar, Gautam Raju Mehta, Kenneth W. Dodd

Lyndsey Turbow, Nancy Guirguis, Praveena Tathineni,
Dana Mueller, Tyler Cooper, Daniel Thompson, Nicholas
Goodmanson, John Weissert, Kourosh Ravvaz, Kenneth W.
Dodd

Internal Medicine, Advocate Christ Medical Center;
Pharmacy, Advocate Christ Medical Center, Hematology
and Oncology, Advocate Christ Medical Center; Critical Care
Medicine, Advocate Christ Medical Center
Background: Thrombotic events despite prophylactic
anticoagulation are a well-recognized complication in patients
diagnosed with severe COVID-19. The appropriate dosage and
indications for anticoagulation remains controversial.
Purpose: To describe the general outcomes of critically ill
COVID-19 patients receiving therapeutic anticoagulation guided
by our expert-driven protocol.
Methods: This retrospective cohort study includes patients
admitted to the intensive care unit between March 3, 2020, and
April 12, 2020, at Advocate Christ Medical Center (Oak Lawn, IL).
Patients taking oral anticoagulants prior to arrival and those started
on therapeutic anticoagulation to prevent extracorporeal membrane
oxygenation (ECMO) circuit thromboses were excluded. The
initiation and dosing of anticoagulation was at the discretion of the
treating clinicians. Informal, institutional indications for initiation
of therapeutic anticoagulation were: D-dimer of >6 times the upper
limit of normal (ULN), sepsis-induced coagulopathy of ≥4, and
clinical evidence of thrombosis. Demographic, laboratory, and
clinical outcomes data were collected. Thrombotic and bleeding
events were adjudicated by 2 trained clinicians or pharmacists.
Results are descriptive.
Results: Of 145 subjects identified, 67 (46%) received therapeutic
anticoagulation. Median (interquartile range [IQR]) age was 61
(56–71) years, median (IQR) body mass index was 32.8 (29–36.7)
kg/m2, 42 (62%) were male, and 44 (66%) were non-White. The
most common comorbidities were hypertension (n=50, 75%)
and obesity (n=46, 69%). The initial therapeutic anticoagulation
method was unfractionated heparin infusion in 63 (94%) and
subcutaneous enoxaparin in 4 (6%). The most common indication
was D-dimer of >6×ULN in 58 (87%), while 4 (6%) were
started on anticoagulation for thrombotic events alone. Median
(IQR) time to initiation was 5 (1.5–8) days; 43 (64%) required
invasive mechanical ventilation at the time of initial therapeutic
anticoagulation. At follow-up, 44 (65%) subjects were discharged
alive, and 23 (34%) had expired. Four (6%) were diagnosed with
5 new thrombotic complications: 3 (4.5%) deep vein thromboses,
1 (1.5%) pulmonary embolism with hemodynamic compromise,
and 1 (1.5%) ischemic cerebrovascular accident. Two (3%) patients
experienced clinically overt gastrointestinal bleeding accompanied
by a decrease in hemoglobin of at least 2 g/dL. No other fatal or
major bleeding complications reported. Minor bleeding events
were identified in 12 (18%) subjects.
Conclusion: In this study, critically ill adults on therapeutic
anticoagulation had a low incidence of new thrombotic
complications and low incidence of major bleeding.
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Internal Medicine, Advocate Christ Medical Center;
Pulmonology and Critical Care, Advocate Christ Medical
Center; Advocate Aurora Research Institute; Emergency
Medicine, Advocate Christ Medical Center
Background: Practitioners have used therapeutic anticoagulation
to prevent the thrombotic complications of the severe acute
respiratory coronavirus 2 (SARS-CoV-2) responsible for the
COVID-19 pandemic. The effect of such an approach on serum
inflammatory markers, and factors associated with survival while
on therapeutic anticoagulation, are not known.
Purpose: This study evaluated the effect of therapeutic
anticoagulation on C-reactive protein (CRP), lactate dehydrogenase
(LDH) ferritin, and D-dimer and also analyzed the association of
several factors with mortality.
Methods: This retrospective cohort study used data collected
from patients diagnosed with SARS-CoV-2 and receiving
therapeutic anticoagulation in the intensive care unit of a
tertiary care center between March 3, 2020, and April 12, 2020.
Indications for initiation of therapeutic anticoagulation included
D-dimer of >6 times the upper limit of normal (ULN), sepsisinduced coagulopathy score of ≥4, or evidence of thrombotic
disease. Data included initial serum markers and repeat values
taken at discreet intervals, along with clinical features and
mortality. Comparisons were made using 2-sided Mann-Whitney
U test. Multivariate analyses for predicting death were calculated
using Cox proportional hazards models.
Results: Of 145 subjects, 67 (46%) received therapeutic
anticoagulation: 58 (87%) for COVID-19 coagulopathy and 12
(18%) for thrombotic events. Initial median (interquartile range)
serum values were as follows: CRP of 14 (9–21) mg/dL, D-dimer
of 8.1 (4.3–18.6) mg/L, ferritin of 1614 (723–2526) ng/mL,
and LDH of 445 (356–629) units/L. Five days after initiation of
anticoagulation, patients had a decrease in all measured median
serum values: CRP of 6.8 (2.5–9), LDH of 385 (297–472),
D-dimer of 4.1 (2.3–7.9), and ferritin of 975 (646–1483); P<0.05
for all). At the time of follow-up, 23 (34%) patients had been
discharged alive, 20 (30%) patients had expired, and 24 (36%)
patients remained in-hospital. Mortality was directly associated
with age (hazard ratio [HR]: 9.05, 95% CI: 1.71–46; P<0.01) and
postanticoagulation D-dimer level (HR: 9.78, 95% CI: 1.81–52.9;
P<0.01) and inversely associated with obesity (HR: 0.27, 95%
CI: 0.80–0.93; P<0.05 for all).
Conclusion: In this patient population, therapeutic anticoagulation
was associated with a decrease in inflammatory markers, suggesting
efficacy of treatment. Anticoagulation may have a particularly
important role in obese patients, as obesity was associated with
higher survival in patients placed on anticoagulation. This study
provides important data for larger, prospective trials.
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Advancing Advance Directives in an Internal Medicine
Residency Clinic
Tanya Shah, Ramandeep Dhaliwal, Zeba Shethwala, Henok
Hardilo, Jasmine Webster, David Hamel, Ankoor Biswas,
Deborah Simpson
Internal Medicine, Aurora Sinai Medical Center; Aurora UW
Medical Group, Family Medicine and Academic Affairs,
Aurora Sinai Medical Center
Background: Research shows 89% of patients prefer advance
directive (AD) conversations be initiated in the outpatient setting,
ideally with their primary care doctor. Only 47% of patients in our
resident clinics who are older than 65 years of age have completed
advance directives documentation on file.
Purpose: To increase AD completion numbers for >65-year-old
patients in an internal medicine residency clinic by 12%.
Methods: We developed a new standardized workflow for all clinic
patients who are >65 years of age to ensure they were receiving
appropriate goals-of-care counseling. During the pandemic, the
workflow was adapted to include virtual AD completion utilizing
a new organizationally approved online platform and incentivizing
clinic teams for AD-specific appointments. The new workflows
were implemented at 1 of 2 internal medicine residency clinics,
with the other used as a control site. Residents completed a series of
educational lectures and simulation exercises on how to engage in
advance care planning discussions in the outpatient setting. Metrics
included health system-provided percentages of AD completion rates,
with overall clinic quality improvement scores and Clinical Learning
Environment Quick Surveys (CLEQS) used as balancing measures.
Results: Between January 2020 and December 2020, our clinic
AD completion improved 1% at the intervention site. Postvirtual AD implementation, AD intervention site completion rate
increased another 1% in January 2021. This marks an overall 4%
AD intervention site improvement compared to the control site
at which AD completion rate decreased by 2% during the same
period. There were no unexpected changes in our overall quality
improvement scores and a pre/post-project implementation
improvement, as measured by CLEQS, in teamwork.
Conclusion: Planning for future health care needs has multiple
benefits for older adults, their loved ones, and the entire health
system. Improving provider comfort with and destigmatizing
advance planning conversations is an essential step in promoting the
completion of AD documentation. As seen with our January 2021
data, better coordination with clinic social work staff through clear
workflows and availability and utilization of online AD completion
platforms is critical in progressing toward goal achievement.
Moving forward, continuing to integrate new virtual AD technology
into clinic operations and provider training appears to facilitate AD
document completion in a more timely and efficient manner.
Opioid Prescribing Practices Following Otologic and
Neurotologic Surgery
Sarah J. Riutta, Aaron G. Benson
Advocate Aurora Research Institute; Otolaryngology Head
and Neck Surgery, Aurora Sinai Medical Center
Background: Surgeons accounted for nearly 37% of opioid
prescriptions dispensed in the United States between 2007 and
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2012. Prescribing opioids for postoperative pain is routine, but
there is little consensus on the appropriate amount to prescribe.
Recent publications have found the number of pills prescribed by
otolaryngologists following ear, nose, and throat procedures varies
widely, and patients typically do not consume the entirety of their
prescription. Given the variability in reported prescribing practices and
limited data available specific to otologic and neurotologic procedures,
there is a need to further examine opioid prescribing practices.
Purpose: To provide insight into opioid prescribing practices following
otologic and neurotologic procedures at Aurora Health Care.
Methods: Medical records of patients who underwent an otologic
or neurotologic procedure at Aurora Health Care between October
1, 2018, and August 24, 2020, were examined for inclusion.
Records were included if patients were not chronic opioid users
prior to surgery and were not admitted to the hospital within 2
weeks of surgery.
Results: A total of 230 patient records met eligibility criteria.
All but 4 patients received a postoperative opioid prescription.
Nearly 90% of prescriptions were written for 30 tablets of 5–325
mg hydrocodone-acetaminophen. Refills were provided to 16% of
patients. The cohort or patients that received refills was significantly
younger, reported higher pain scores during post-anesthesia care
unit (PACU) recovery, and received significantly more intravenous
fentanyl during the perioperative period compared to the patient
cohort that did not receive a refill. Patients were more likely to
receive a refill if they had preoperative otalgia or received any
opioid analgesic during PACU recovery. There was no significant
effect of sex, race, ethnicity, body mass index, smoking status, or
recent preoperative narcotic exposure on whether a patient received
a refill of opioid pain medication.
Conclusion: Younger age, preoperative otalgia, high inpatient
opioid dose requirements, and high inpatient pain scores were
associated with refills of opioid prescriptions following otologic
and neurotologic surgery. Further research is needed to clearly
define factors otologic surgeons should consider for tailoring
postoperative opioid prescriptions to individual patient needs.
National Cancer Database Analysis of Outcomes in
Patients Diagnosed With Glioblastoma
Maharaj Singh, Parvez Akhtar, Richard A. Rovin
Advocate Aurora Research Institute; Neurosurgery, Aurora
Neurosciences Innovation Institute
Background: Glioblastoma is one of the aggressive types of cancer
that can occur in the brain or in spinal cord. There has been progress
in understanding in recent years; however, prognoses are still
very poor. Treatment of glioblastoma requires a multidisciplinary
approach based on understanding the pathophysiology of the
disease, which can eventually lead to a better prognosis for patients.
Purpose: To describe the demographics for the patients
diagnosed with glioblastoma and evaluate association of patient
characteristics, socioeconomic status, and treatment with overall
survival at 1, 2, and 5 years of diagnosis.
Methods: We analyzed the National Cancer Database, which
provides broad and detailed information on demographic
characteristics, treatment modalities, and survival outcome for
patients diagnosed with glioblastoma. Descriptive statistics,
Kaplan-Meier curve, and Cox proportional hazards regression
were used to analyze the data. For all statistical analyses, SAS 9.4
software (SAS Institute Inc.) was used.
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Results: A total of 124,282 patients were identified with diagnosis
of glioblastoma from 2004 through 2016. The study population
included patients with ICD-O-3 histology codes 9440, 9441, and
9442 and tumor sites for central nervous system and brain (C71.0–
C71.9 and C72.0–C72.3). Data with missing vital status (dead,
alive) were excluded from the analysis. Population was 57.4%
male, 87% non-Hispanic White (NHW), 5.5% non-Hispanic
Black (NHB), 5% Hispanic, and rest were from the “Other” race
category. Adjusted hazard ratio for mortality was significantly
higher for males (1.06) and for NHW (1.3 compared to Hispanics,
1.2 compared to NHB, and 1.3 compared to “Others”). Similarly,
hazard ratios were higher for low-income group (1.03), uninsured
(1.06), and for patients with higher comorbidity scores (1.2–1.4).
The patients with treatment such as surgery (0.57), radiation (0.69),
immunotherapy (0.83), or chemotherapy (0.64) had lower hazard
ratio for mortality. Every 10-year increase in age also was found
to cause a 1.27 times increase in mortality. Respective overall
survival percentages at 1, 2, 3, and 5 years were only 42%, 19%,
11%, and 6% of the patients diagnosed with glioblastoma.
Conclusion: Female, Hispanic and Asian/Pacific Islanders, and
younger patients had better survival. Patients who underwent
treatments such as surgery, chemotherapy, immunotherapy,
hormonal therapy, and radiation had better survival probability.
Risk Factors for Developing Unpleasant Paresthesia
After Implantation of Permanent Spinal Cord Stimulators
Nebojsa Nick Knezevic, Tabish Aijaz, Alvaro CamachoOrtega, Kenneth D. Candido
Anesthesiology, Advocate Illinois Masonic Medical Center
Background: Spinal cord stimulators (SCS) have become a
promising option to treat chronic pain syndromes; nevertheless,
there are challenges that might compromise the effectiveness and
lead to higher health care costs. Unpleasant paresthesia/dysesthesia
is one of these challenges.
Purpose: To determine the incidence of unpleasant paresthesia
after implantation of permanent SCS and find the risk factors for
its development.
Methods: After institutional review board approval, a retrospective
analysis was conducted of prospectively collected data of patients
that had permanent percutaneous SCS implanted. We included
patients >18 years of age with chronic intractable nonmalignant
pain of the trunk and/or limbs who had SCS implanted for at least
2 years. We used SPSS 22.0 software (IBM Corp.) to perform
statistical analysis.
Results: A total of 104 patients had at least 24 months of followup after implantation of permanent SCS. Mean age of patients was
56.99 years, and the average body mass index was 29.7. Mean pain
score before implantation, measured via numeric rating scale (NRS),
was 8.05, which was reduced to 5.6 after 24 months. Excluding
the need for routine reprogramming, 45% of the complication
events presented within the first 12 months of follow-up (P=0.022).
The most common complication in our study sample was the
development of unpleasant paresthesia/dysesthesia, which was
reported by 27% of participants. There was no association between
paresthesia and age, gender, or body mass index. We found a
statistically significant correlation between current tobacco use and
cases of uncomfortable paresthesia and/or dysesthesia in patients
that received the permanent SCS (P=0.001), and 38% of the cases
required or requested explantation of the device (P=0.028). During
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the follow-up period, active tobacco users and former tobacco users
had a lower-than-average mean NRS reduction of 2.74 ± 2.30 and
2.90 ± 3.90, respectively, when compared to a 3.33 ± 2.67 mean
NRS reduction in never tobacco users; however, no statistical
significance was observed between the groups (F(<1) P=0.60).
Conclusion: Unpleasant paresthesia seems to be more common
than originally thought, with an unclear cause. According to our
study findings, longstanding tobacco users being treated with SCS
are more prone to develop unpleasant paresthesia/dysesthesia when
compared with non- and former tobacco users.
Clinical Characteristics and Outcome of Children
Hospitalized With SARS-CoV-2–Related Illness: A SingleCenter Descriptive Cohort Study
Varsha P. Gharpure, Kenneth W. Dodd
Advocate Children's Hospital;
Advocate Christ Medical Center

Emergency

Medicine,

Background: Pattern of presentation and hospital course of
children affected with SARS-COV-2 infection is distinct from
adults.
Purpose: To describe characteristics and outcomes of children
affected by SARS-CoV-2–related illness presenting to two
campuses of a Midwestern community-based children’s hospital.
Methods: Data of symptomatic hospitalized children with
laboratory-confirmed SARS-CoV-2 infection or epidemiologically
related multisystem inflammatory syndrome in children (MIS-C) —
as defined by Centers for Disease Control and Prevention (CDC)
— who were reported to the Society of Critical Care Medicine’s
VIRUS COVID-19 registry from two campuses of Advocate
Children’s Hospital (Park Ridge, IL) between March 1, 2020, and
March 31, 2021, were retrospectively analyzed. Primary outcome
measure was in-hospital mortality; secondary outcome measures
were hospital length of stay, need for admission to the intensive
care unit, and organ support. Data are reported as percentage,
number, or median (interquartile range) and analyzed with Fisher’s
exact, chi-squared or Mann-Whitney U tests as appropriate.
Results: A total of 186 children were admitted during the study
period (median age: 5.7 [1.7–12.2] years; male gender: 60%;
Black race: 17%; Hispanic ethnicity: 44%), and 61 met the CDC
definition of MIS-C. SARS-COV-2 PCR assay was positive in 152,
while immunoglobulin G antibody was positive in 59. Overall,
180 patients were discharged from the hospital, 5 were transferred
to another facility, and 1 patient on chronic noninvasive home
ventilation died; 133 were reported to be alive at day 28, and the
rest were lost to follow-up. Median duration of hospitalization
was 3.6 (1.9–5.8) days; 89 children needed intensive care
(median duration: 2.5 [1.3–50] days). Modalities of organ support
included invasive mechanical ventilation (n=25, median of 1.7
[0.1–90] days), noninvasive ventilation (n=11), high-flow nasal
canula (n=36), nitric oxide (n=7), and extracorporeal membrane
oxygenation (n=3). Compared to those without MIS-C, children
presenting with MIS-C were older (8 [4.3–10.9] years vs 4.3 [0.5–
13.45] years; P=0.01), less likely to have comorbidities (P=0.002),
and more likely to need intensive care (P<0.001).
Conclusion: Children demonstrate two distinct phenotypic
presentations related to SARS-CoV-2 infection, a typical COVID-19
type and a distinct multisystem inflammatory syndrome. Early
identification of risk factors is essential for appropriate intensive
care utilization and management decisions.
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Comparison of Treprostinil and Phosphodiesterase Type
5 Inhibitor for the Treatment of Systemic Sclerosis: A
Retrospective Study
Sheldon R. Garrison, Angela A. Navarrete-Opazo, Dianne L.
Zwicke, Alex M. Maley, Maharaj Singh, Sara Paulus
Advocate Aurora Research Institute; Transplant Cardiology,
Aurora St. Luke’s Medical Center; Aurora Dermatology,
Advocate Aurora Health
Background: Systemic sclerosis is a rare connective tissue
disease affecting approximately 100,000 people in the United
States. Onset is typically between 30 and 60 years of age, with
gradual progression over 11–22 years. Systemic sclerosis is
characterized by diffuse fibrosis of the skin and internal organs,
vascular insufficiency, and autoimmune dysregulation. Nearly
half of systemic sclerosis patients develop digital ulcers, which
are profoundly painful, slow to heal, and may progress to
osteomyelitis or even amputation. Despite the high unmet need,
only one drug has been approved by the U.S. Food and Drug
Administration for the treatment of systemic sclerosis-associated
interstitial lung disease. Thus, there is an immediate need to
identify and test therapeutics for the treatment of digital ulcers in
systemic sclerosis.
Purpose: To compare the efficacy of treprostinil and
phosphodiesterase type 5 (PDE5) inhibitor for the treatment of
cutaneous systemic sclerosis.
Methods: A retrospective chart review of adult patients with a
clinical diagnosis of scleroderma or systemic sclerosis within
Advocate Aurora Health was performed. Patients received
either treprostinil, PDE5 inhibitor, or nonactive treatment (No
Tx), beyond antibiotic and pain medication, for digital ulcers
between January 2011 and March 2020. Treatment efficacy was
determined by the rate of digital healing and amputations in each
group. One-way ANOVA was used for comparisons of the groups.
For all statistical tests, an alpha of 0.05 was used. All statistical
analysis was done using Prism (GraphPad Software) and SAS 9.4
(SAS Institute Inc.) software. This study was approved by the
institutional review board.
Results: Digital ulcers were observed in 12 of 31 (38%) patients
from the treprostinil-treated group, 7 of 14 (50%) PDE5-treated
patients, and 8 of 13 (62%) No Tx patients. Treprostinil was
successfully used to reduce ulcer burden and avoid amputation
in 100% of patients (12 of 12) with digital ulcers. All digital
ulcers in treprostinil-treated patients with systemic sclerosis fully
resolved, and no new lesions were observed during treatment.
Treatment was well tolerated with no major complications. In
the PDE5-inhibitor cohort, digital ulcers healed in only 14% of
patients (1 of 7); 0% of patients (0 of 8) improved in the No Tx
group (P<0.001).
Conclusion: The findings support the potential efficacy of
treprostinil as a therapy for the treatment of digital ulcers in
systemic sclerosis.

Prognostic Implications of Vitamin D in Patients With
a Hematologic Malignancy at a Large Health System in
Wisconsin
Daniel M. Mundt, Marianne Klumph, Kayla Heslin, Michael
A. Thompson
Internal Medicine, Aurora Sinai Medical Center; Aurora
UW Medical Group; Center for Urban Population Health;
Oncology Precision Medicine Program, Advocate Aurora
Research Institute
Background: Vitamin D deficiency (VDD) is common in the United
States (~10%). Epidemiological studies correlate with increased
risks for cancer, infections, autoimmune, and cardiovascular diseases
when vitamin D levels are less than 20 ng/mL. Single-center studies
have shown that VDD at diagnosis may be associated with poorer
prognosis in various cancers, including hematologic malignancies
for which therapy response may be modulated.
Purpose: To assess the incidence and prevalence of VDD among
patients with hematologic malignancies in a large community
health system.
Methods: Patients with hematologic malignancies from January
2012 to December 2019 were evaluated from the electronic health
record of Aurora Health Care. Institutional review board approval
was obtained. Statistics included descriptive (demographics) and
categorical variables analyzed using chi-squared test. Continuous
variables were analyzed using t tests.
Results: In all, 4485 patients with hematologic malignancies across
17 oncology clinics were evaluated. Mean age was 68.3 years (range:
18–99), and the study population was predominantly White (89%).
Patients receiving chemotherapy, immunotherapy, and radiation
therapy were more likely to be tested (P>0.01). The most common
hematologic malignancy was chronic lymphocytic leukemia (21%),
followed by diffuse large B-cell lymphoma (18%). A total of 645
(14%) patients had a vitamin D test done within a 3-month window
either before or after diagnosis, and 172 of 645 (27%) had VDD.
Patients with multiple myeloma (25%) were the most likely to be
tested for VDD, whereas individuals with primary myelofibrosis
(7%) were least likely. VDD was associated with an increased time
to initial treatment for all combined hematologic malignancies.
Conclusion: Despite a reported prognostic value, vitamin D levels
were infrequently assessed at diagnosis of hematologic malignancy.
The role of VDD and treatment outcomes will be evaluated by
stratifying hematologic malignancy tumor types and therapies.
Universal COVID-19 Testing in Labor and Delivery Patients
at Aurora BayCare Medical Center: Preliminary Results
Jennifer K. Homa, Taylor A. Romdenne, Christina C. Renz,
Kelly K. Malloy
Advocate Aurora Research Institute; Aurora BayCare
Medical Center
Background: Pregnant women and their fetuses have been
significantly impacted with increased risk of complications by
emerging infections. Little is known regarding the impact of the
novel SARS-CoV-2 infection (COVID-19) on delivery outcomes.
Purpose: To evaluate rates of asymptomatic COVID-19 infection
among laboring patients in northeast Wisconsin and any impact on
delivery outcomes.
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Methods: A retrospective public health surveillance project was
conducted as part of a universal COVID-19 testing policy at
Aurora BayCare Medical Center (Green Bay, WI) with laboring
patients from April 14, 2020, to July 31, 2020. Chart reviews
were conducted to collect demographic data, COVID-19 results
(mother and infant), and delivery outcomes (Apgar score, delivery
method, gestational age, and arterial blood gas). Descriptive and
frequency statistics were used to summarize the characteristics of
the study population.
Results: Of the 487 singleton deliveries included, 9 mothers tested
positive, 477 mothers tested negative, and 1 mother refused to be
tested. Overall COVID-19 positive rate in northeast Wisconsin was
1.8% (n=9). The asymptomatic COVID-19 positive rate was 1.6%
(n=8). Two mothers (0.4%) were symptomatic; however, only 1
tested positive, yielding a symptomatic COVID-19–positive rate
of 0.2% (n=1). None of the newborns in this sample tested positive
for COVID-19. Notably, although only 9.4% of our sample were
Hispanic women, 88.9% (n=8) of the COVID-19–positive cases
were among Hispanic women.
Conclusion: Racial and ethnic disparities in COVID-19 cases have
been observed, and these preliminary findings may help to support
and guide local outreach efforts in northeast Wisconsin. Additional
data are needed to monitor the impact of COVID-19 infection on
pregnant women and their newborns.
Encouraging Opioid Abstinence Through Contingency
Management: A Pilot Study
Elizabeth Wanninger, Mindy R. Waite, Rebecca Dizon-Ross,
Ariel Zucker
Aurora Behavioral Health Services, Advocate Aurora
Research Institute; University of Chicago Booth School of
Business; Department of Agricultural & Resource Economics,
University of California, Berkeley
Background: Contingency management (CM) is an intervention
that uses planned contingencies to change behavior. Typically, CM
targets consequences to reward or punish behavior. CM has been
tested across many behaviors, including substance use. Although
CM has shown effectiveness for substance use populations,
questions remain about the most efficient versus effective
intervention designs. CM mobile applications have been developed
to increase efficiency. However, effectiveness of automated CM
mobile apps is not yet established.
Purpose: To test effectiveness of CM delivery via mobile app. This
pilot tested proposed study methods and assessed whether opioid
abstinence levels differed between treatment groups.
Methods: Patients were eligible if recently enrolled in partial
hospitalization or intensive outpatient programs for an opioid use
disorder at Aurora Health Care. Participants were randomly assigned
to 1 of 3 groups. The Inputs group received differential reinforcement
of alternative responses, including taking oral buprenorphine and
attending substance use treatment. The Outcomes group received
differential reinforcement of other behavior-completing opioidnegative saliva tests. The Combined group received both Inputs and
Outcomes reinforcement. Activities were prompted and rewarded
through the DynamiCare app (DynamiCare Health). All groups
were provided an average of 13 tasks per month. Primary outcome
was opioid-negative status on drug tests at 4-week intervals.
Secondary outcomes included the number of successful tasks and
substance use program completion rate.
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Results: Drug screens were obtained at 59% of the 4-, 8-, and 12week interval markers. Respective rates of opioid-negative drug
tests completed for weeks 4, 8, and 12 were 80%, 80%, and 57%
for Inputs; 83%, 100%, and 100% for Outcomes; and 100%,
75%, and 60% for Combined. Inputs participants averaged 13.6
successful behaviors, Outcomes averaged 20.8, and Combined
averaged 11.8. Completion rates for substance use treatment were
70% for Inputs, 75% for Outcomes, and 75% for Combined.
Conclusion: The pilot study showed success in enrolling
patients and collecting outcomes data. However, opportunities
for improvement were identified. Increased engagement in
outcomes testing will require larger incentives. Also, due to low
app engagement by a subset of participants across groups, practice
opportunities should be added in the first week of enrollment.
Providing participants earlier access to rewards may increase
potential for maintaining opioid abstinence.
Cardiac, Renal, and Liver Function in Neonates With
Hypoxic Ischemic Encephalopathy Treated With
Therapeutic Hypothermia
Gospodin Stefanov, Timothy Colombo, Preetha Prazad,
Ramona Donovan, Lorene Schweig
Neonatology, Advocate Children’s Hospital; Rosalind
Franklin University of Medicine and Science; Advocate
Aurora Research Institute
Background: Therapeutic hypothermia (TH) reduces the brain
injury and negative multiorgan impact of perinatal asphyxia in
neonates. TH is an established treatment for perinatal asphyxia,
but there is a lack of research data to explain how TH modulates
cardiac, renal, and hepatic dysfunction. Moreover, it is unclear if
these functional changes can predict neonatal outcomes.
Purpose: To evaluate cardiac, renal, and liver function in neonates
treated with TH and to determine whether various biochemical/
functional parameters are significant predictors of mortality.
Methods: A retrospective electronic medical record review of 47
neonates treated with TH because of perinatal asphyxia in a Level
IV neonatal intensive care unit. All study procedures were approved
by the local institutional review board. Subjects were divided into
groups dependent on their: 1) gestational age at birth: late preterm
or term; 2) size at birth: small or appropriate for gestational age;
and 3) outcome: alive (n=40) or deceased (n=7). Data collected for
analyses included cardiac, renal, and hepatic function parameters,
concomitant medications/treatments, and perinatal factors. Oneway ANOVA and Pearson’s correlation analyses were used to
compare variables between the independent groups. Fisher’s exact
test was used for categorical variables.
Results: There was no significant difference in echocardiographic
cardiac function parameters (ejection fraction, systolic function,
end-diastolic left ventricular internal diameter [LVIDd]) between
the alive and deceased groups (P>0.05). No significant correlation
was found between ejection fraction, LVIDd, or systolic function
and any of measured cardiac (troponin I, creatine kinase-MB), renal
(blood urea nitrogen [BUN], BUN/creatinine ratio, glomerular
filtration rate [GFR]), or hepatic (alanine aminotransferase [ALT],
aspartate aminotransferase [AST], alkaline phosphatase, lactic
acid) biomarkers (P>0.05 for all). Mean GFR and urine output
were significantly lower and serum creatinine was significantly
higher in the deceased group than the alive group at 24, 48, 72,
and 96 (±4) hours after birth (P<0.05 and P<0.005, respectively).
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Mean serum BUN was not significantly different at any time
point between the alive and deceased groups (P<0.05). Mean
serum ALT, AST, and lactic acid were significantly higher in the
deceased group than the alive group at 24 hours of life (P<0.05).
No significant differences were found among the cardiac, renal,
and liver function parameters between the gestational age or size
at birth groups (P>0.05 for all).
Conclusion: Cardiac, renal, and liver function parameters did
not significantly differ based on gestational age or by weight for
gestational age in neonates treated with TH. Markers of renal and
hepatic function may be predictive of survival in neonates with
perinatal asphyxia being treated with TH.
Evaluation of Partial Thromboplastin Time Versus AntiXa Levels in Heparinized Patients With Left Ventricular
Assist Device
Bret Lentz, Jon Godden, Rachel Pedersen
Pharmacy, Aurora St. Luke’s Medical Center; Biostatistics,
Aurora St. Luke’s Medical Center
Background: Various studies have shown a discordance between
activated partial thromboplastin time (aPTT) and anti-Xa levels in
heparinized patients with a left ventricular assist device (LVAD).
This discordance could lead to unwanted clinical outcomes if
heparin therapy is not properly assessed in these high-risk patients.
Patients with LVAD require precise monitoring to reduce the risk
of both thrombus and hemorrhage. Aurora St. Luke’s Medical
Center (Milwaukee, WI) currently utilizes aPTT to routinely
monitor heparinized patients. The goal of this retrospective review
is to determine if aPTT and anti-Xa levels correlate and represent
accurate heparin serum concentrations.
Purpose: To assess correlation of aPTT and anti-Xa levels in
heparinized patients with LVAD.
Methods: We conducted a retrospective observational assessment
of patients with LVAD requiring intravenous heparin who were
monitored with aPTT and anti-Xa levels simultaneously. Serial
paired levels of anti-Xa and aPTT were analyzed. Primary outcome
was to assess the correlation between aPTT and anti-Xa based
off hospital therapeutic heparin metrics. Categorical variables
were described using frequency and percentages, and continuous
variables were described using mean ± standard deviation or
median with interquartile range. A simple Kappa estimate was used
to calculate agreement between anti-Xa and aPTT group levels. The
project was determined to not constitute human subjects research
and thus did not require institutional review board oversight.
Results: A total of 22 patients with 191 serial-paired anti-Xa and
aPTT levels were included for analysis. Mean age at implant was
54.5 ± 13.3 years, 17 (77.3%) were male, and 19 (81.8%) implants
were classified as destination therapy. Of the 191 levels, 42 (22%)
were indicated as subtherapeutic by both aPTT (ie, <45) and antiXa (ie, <0.3). There were 82 (43%) indicated as therapeutic by
aPTT (ie, 45–70) but subtherapeutic by anti-Xa. Only 37 (19%)
were indicated as therapeutic by both aPTT and anti-Xa. Finally, 2
(1%) were indicated as supratherapeutic by both aPTT and anti-Xa
(Kappa estimate: 0.1, 95% CI: 0.01–0.18).
Conclusion: Therapeutic groupings indicated by aPTT levels were
in slight agreement when compared with anti-Xa. The most common
disagreement group was where aPTT indicated a therapeutic range
and anti-Xa indicated subtherapeutic. In our institution, this tended
to overestimate the concentrations of heparin in the body.
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Detrimental Oxygen: Oxygen Supplementation in Patients
With ST-Segment Elevation Myocardial Infarction
Gabrielle Rubin, Namra Butt, Sorabh Kothari, Moustafa
Nagui Sabri
Cardiology, Advocate Lutheran General Hospital; Cardiology,
Advocate Christ Medical Center
Background: There is evidence that supplemental oxygen
administration in an acute myocardial infarction is associated with
worse outcomes and larger infarct size.
Purpose: Currently, in the emergency room (ER), patients are
being placed on oxygen supplementation regardless of their oxygen
saturations. This quality improvement project aimed to reduce
the number of patients with ST-segment elevation myocardial
infarction (STEMI) and normoxia receiving supplemental oxygen
in the ER by educating the ER staff about the harmful effects of
oxygen in STEMI patients.
Methods: We retrospectively reviewed our acute STEMI
population from February 1, 2020, to November 25, 2020, to
assess how many of these patients were inappropriately placed
on supplemental oxygen. We used a cut-off value of Sp02 greater
than 90% as a threshold for inappropriate supplementation,
in accordance with the published literature. We then provided
education to all first point-of-care staff members on the appropriate
use of supplemental oxygen and measured for changes in behavior.
Our aim was to reduce inappropriate supplemental oxygen use by
50% in 3 months.
Results: Of the 126 total patients identified over the study period,
79% were placed on supplemental oxygen despite having an
oxygen saturation greater than 90%.
Conclusion: We identified a clear potential for harm with excessive
use of supplemental oxygen for acute STEMI patients. Our goal
is to obtain follow-up data at 3-month intervals to monitor for
improvement, with plans to provide re-education if our goal of a 50%
reduction in inappropriate supplemental oxygen use is not achieved.
Evaluation of Rocuronium Dosing in Rapid Sequence
Intubation Based on Ideal Versus Nonideal Body Weight
in Obese Patients: A Prospective, Observational Study
Amanda Lewandowski, Alaa Sulh, Michael Cirone, Mary
Hormese, Marc McDowell
Pharmacy, Advocate Christ Medical Center; Pharmacy,
Loyola University Medical Center; Emergency Medicine,
Advocate Christ Medical Center; Pharmacy, Northwest
Community Hospital
Background: Rapid sequence intubation (RSI) that provides
adequate paralysis while reducing potential undersedation can be
difficult in obese patients. Pharmacokinetic parameters play an
important role in dosing of rocuronium, as it has low lipophilicity.
Theoretically, rocuronium dosing should be based on ideal body
weight, as accumulation does not occur in adipose tissue. In obese
patients, no guideline-recommended dosing strategies exist for
the use of rocuronium for RSI in the emergency department (ED),
therefore dosing remains dependent on practitioner preference
toward total body weight, ideal body weight, or adjusted body
weight. A paucity of data has compared the use of rocuronium in
obese patients based on different body weights. However, these
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studies took place in a surgical setting and not in the ED, therefore
demonstrating the need for more data in an ED setting.
Purpose: To compare intubation conditions, duration of paralysis,
and incidence of suboptimal sedation after intubation in obese
patients requiring RSI with rocuronium in the ED.
Methods: This is a single-center, prospective, observational study.
Subjects ≥18 years of age with a total body weight ≥30% greater
than ideal body weight or a body mass index of ≥30 kg/m2 who
presented to the ED requiring RSI with rocuronium were eligible
for enrollment. Rocuronium was dosed according to physician/
pharmacist preference per current ED practice. For the calculation
of rocuronium dose based on preferred weight, the pharmacist either
utilized height to calculate ideal body weight or, when available,
actual weight measurement obtained using either standard ED
process or by reviewing prior documentation in the chart. After
intubation, the physician completed a brief survey to assess intubation
conditions utilizing a validated 9-point survey scoring system. The
pharmacist noted height and weight used for the calculation of the
dose, dose of rocuronium, time of medication administration, time
of intubation, need for any repeat dose of paralytic, and time of
muscle function recovery. Endpoints assessed included outcome of
optimal intubation conditions, duration of paralysis, and incidence
of suboptimal sedation (defined as the percentage of patients
experiencing hypertension or tachycardia postintubation).
Results: Intubation was deemed “excellent” in 70.3% of subjects
whose weight was calculated using standard ED process and in
67.9% of those with weight obtained from chart documentation;
only the latter group received any intubation assessments of
“poor” (6.7%). Differences between groups when comparing
noninferiority, first pass success, postintubation hypertension,
and postintubation tachycardia were not statistically significant.
For duration of paralysis, mean time to muscle recovery was 71
minutes (interquartile range: 57–96) for 40 subjects using total
body weight and 43 minutes (40–60) in 33 subjects using ideal
body weight (P<0.01).
Conclusion: Ideal body weight dosing of rocuronium is suggested
to be noninferior to total body weight dosing in obese patients
who require RSI in the ED. This sample size demonstrated
similar efficacy of intubation conditions with shorter duration of
paralysis between the two dosing-by-weight strategies. Follow-up
superiority studies with a larger patient population are suggested to
determine if there is a difference in optimal intubation conditions
between dosing based on ideal body weight or total body weight.
Rocuronium Versus Succinylcholine in the Traumatically
Injured Brain: A Prospective Pilot Study
Nadine Alwawi, Lauren Stambolic, Marc McDowell, Sabrin
Jaber, Brook Walsh, Ellen C. Omi, Robert Mokszycki
Pharmacy, Advocate Christ Medical Center; Stanford
University Medical Center; Little Company of Mary Hospital;
Trauma Surgery, Advocate Christ Medical Center; University
of Massachusetts
Background: Acute traumatic brain injury (TBI) often requires
rapid sequence intubation (RSI) to protect patients’ airways. RSI
begins with pharmacologic induction, followed by paralysis with
agents such as rocuronium or succinylcholine. These medications
benefit from a rapid onset and a relatively short duration. Previous
retrospective literature demonstrated a mortality benefit favoring
rocuronium over succinylcholine.
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Purpose: To assess mortality, among other outcomes, following
RSI with rocuronium compared to succinylcholine for patients
presenting to the emergency department (ED) with acute TBI.
Methods: This ongoing study identified patients for inclusion as
of September 1, 2018. The study population consists of patients
presenting to the ED with acute TBI who undergo RSI with either
succinylcholine or rocuronium. Demographics recorded include
age, sex, race, severity of TBI, and initial Glasgow Coma Scale
(GCS). Exclusion criteria include: patient age of <18 years, surgical
airway placed, pregnant at time of enrollment, cardiac arrest
occurred prior to intubation, or intubation was attempted prior to
arrival. Primary clinical outcome evaluated was incidence of inhospital mortality. Secondary outcomes measured both hospital
and intensive care unit (ICU) length of stay (LOS). A sample size
of 200 was calculated to detect a 20% difference in mortality.
Results: Of 77 patients evaluated in the study thus far, 60 were
included for evaluation and 17 were excluded. Within the inclusion
population, 42 patients were administered succinylcholine prior
to intubation and 18 patients were administered rocuronium.
Baseline demographics were comparable between both groups.
Anticoagulant (5 vs 2; P=0.9) and antiplatelet (3 vs 3; P=0.35)
use was reported in both groups. Prior to intubation, average GCS
between the succinylcholine and rocuronium arms (6.5 vs 5.7,
respectively; P=0.42) did not show a significant difference. No
statistical difference was detected in the incidence of in-hospital
mortality (33.3% vs 27.8%; P=0.67), in-hospital LOS (13 vs 9.5
days; P=0.43), or ICU LOS (7.4 vs 5.7 days; P=0.39) between the
two treatment groups.
Conclusion: Interim results from this ongoing study are
inconclusive. These results prompt further investigation with
additional patients enrolled.
The Palliative Care Symptoms Assessment Tool and the
Palliative Care Referral Criteria Index’s Major Criteria
Were Equally Effective at Increasing Palliative Care
Referrals
Nora Badi, Alexander Schwank, Marianne Klumph, Kavita
Sharma
Hospice and Palliative Care Medicine, Aurora Sinai Medical
Center; Aurora UW Medical Group; Center for Urban
Population Health; Palliative Medicine, Aurora St. Luke’s
Medical Center
Background: There is growing evidence that early access to
palliative care specialists can have a positive impact on quality of
life through symptom management, reducing hospital admission
and length of stay, improving overall patient care by addressing
goals of care and health care directives, and even prolonging
survival of patients with cancer. However, a main barrier to
providing this care early and on time is the difficulty in identifying
patients who could benefit from it.
Purpose: To compare the effectiveness of the Palliative Care
Symptoms Assessment (PCSA) tool with the major and minor
criteria of the Palliative Care Referral Criteria Index (PCRCI)
in appropriately identifying and creating an effective method for
referrals to palliative care services within the Vince Lombardi
Cancer Clinic at Aurora Sinai Medical Center (Milwaukee, WI).
Methods: Patients undergoing transfusion at the Vince Lombardi
Cancer Clinic for an oncology-related diagnosis who either filled
out a PCSA or met the major or minor criteria of the PCRCI were
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identified via chart reviewed. Patients were referred to palliative
care services based on a calculated score for the PCSA. Referral
by PCRCI major criteria occurred if at least 1 of its criterions
were met; the same standard applied to PCRCI minor criteria.
Nonparametric methods were utilized for within-group and
between-group differences. A P-value of 0.05 was considered
statistically significant.
Results: Overall, 27 patients (38% female) were included in
the study sample, for which average age was 59 ± 12 years. The
PCSA and PCRCI major criteria referred a similar percentage of
patients (89% vs 85%; P=0.69). By contrast, the PCRCI minor
criteria referred significantly fewer patients than the PCSA (48%
vs 89%; P=0.001). An association between the screening tools
was determined by the percentage of clients who were referred
by both the PCSA and PCRCI major criteria (n=22 [82%];
P=0.05) or both the PCSA and PCRCI minor criteria (n=13
[48%]; P=0.22). Total PCSA scores between those referred vs not
referred within PCSA, major criteria, and minor criteria were as
followed: median (interquartile range) of 50 (24–79) vs 6 (0–8)
(P=0.01); 61 (42–84) vs 21 (9–57) (P=0.02); and 42 (17–83) vs
39 (3–74) (P=0.38).
Conclusion: The PCSA and the PCRCI’s major criteria were
equally effective at referring patients, whereas the PCRCI’s
minor criteria performed poorly. Future research should focus
on whether the major criteria would still be as effective with the
exclusion of the severe symptoms criteria, as severe symptoms
are determined by the PCSA.
KALMED: Ketamine for Acute Agitation Management in
the Emergency Department
Lauren Stambolic, Marc McDowell, Dharati Desai, Jaxson
Burkins, Nadine Lomotan, Tasneem Ahmed, Stephany
Nuñez Cruz
Pharmacy, Advocate Christ Medical Center; Emergency
Department, Advocate Christ Medical Center
Background: Acute agitation is common in the emergency
department (ED). It is crucial to efficiently relieve agitation in
these patients for the safety of the patients and the health care team.
Numerous studies conducted in the prehospital setting and in the
ED have found ketamine to be an effective agent with more rapid
onset of action compared with benzodiazepines or antipsychotics
for initial control of acute agitation. To date, there are no data
comparing reduced-dose (~2 mg/kg) vs standard-dose (4–5 mg/kg)
intramuscular ketamine for acute agitation.
Purpose: To assess the effectiveness and safety of intramuscular
ketamine of <2.5 mg/kg vs >2.5 mg/kg for acute agitation.
Methods: This was a single-center, retrospective, 2-arm study
cohort. Patients who received intramuscular ketamine for acute
agitation in the ED were included. Exclusion criteria included
patients under 18 years old or administration of a concomitant
sedative agent during ketamine administration. Primary outcome
was resolution of agitation at 15 minutes (±10 minutes) after
ketamine administration. Resolution of agitation was defined as
documentation from a health care provider, lack of administration
of another sedative agent within 30 minutes from ketamine
administration, or the ability to complete necessary procedures.
Secondary outcomes included use of intramuscular or intravenous
rescue medications within 30 minutes after ketamine administration,
adverse events, and time to medical clearance.
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Results: There was no statistically significant difference in
resolution of agitation between the low-dose and high-dose
intramuscular ketamine groups (91.4% vs 100%, respectively;
P=0.54). There was a nonsignificant increase in intubation in
the low-dose group compared to the high-dose group (11.4% vs
6.3%; P=1.00); however, the majority of intubations (4 of 5) were
unrelated to ketamine administration.
Conclusion: Expanding this project’s time frame for data
collection is needed to yield sufficient power and better inform
future prospective study design.
Access to Targeted Online Educational Resources
Before and in the Midst of a Pandemic
Deborah Simpson, Kathryn Denson, Amanda Szymkowski,
Debra Mooney, Steven Denson, Edmund H. Duthie, Jr.,
Michael L. Malone
Family Medicine and Academic Affairs, Aurora Sinai Medical
Center; Geriatrics, Medical College of Wisconsin; Geriatrics,
Aurora Sinai Medical Center; Aurora Senior Services, Aurora
UW Medical Group
Background: In 2020 medical education shifted to virtual settings
driven by pandemic-related precautions. New venues for education
were created. Long-standing virtual forums, such as a monthly 1-hour
most difficult case conference (MDCC) series for geriatric fellows
across the country, continued without disruption — transitioning
from audio-only to include video. As an existing national forum,
the Advocate Aurora Health (AAH)-sponsored MDCC is uniquely
positioned to evaluate if access rates for educator-recommended
virtual resources changed from prepandemic to midpandemic.
Understanding rate change during times of stress is essential for
educators to knowledgeably adapt instruction.
Purpose: To determine if access rates changed for educatoridentified virtual resources referenced during a pandemic.
Methods: Geriatric Fast Facts (GFF) is a collaboration between
AAH and the Medical College of Wisconsin that provides a
virtual resource for teachers/learners and contains peer-reviewed,
evidence-based summaries on topics essential to older adult care via
a searchable website (www.geriatricfastfacts.com). A GFF specific
to each MDCC monthly case was provided via a link to conference
participants. Google Analytics data were used to determine if site
traffic for the MDCC-targeted GFF differed pre- vs midpandemic.
Average daily access rate 12 days prior to each MDCC session was
calculated as a control and compared to the access rates on the
MDCC day. Site traffic data are typically stable day-to-day, and
there is no site registration.
Results: On average, MDCC attendance increased by 45% from
prepandemic (13 sessions held during May 26, 2019–February
19, 2020) to midpandemic (13 sessions held during April 15,
2020–November 18, 2020). Access rates to MDCC-targeted
GFF remained constant from pre- to midpandemic given MDCC
participation increase. MDCC-targeted GFF site visits averaged
6.06 pre- and 10.09 midpandemic, a 44% increase (average
increase of 4.9 per MDCC session). Individuals stayed on the GFF
website, visiting 16.54 other pages pre- and 25.19 midpandemic, a
34% increase (average increase of 8.7 per MDCC session).
Conclusion: MDCC-linked GFF access and other page visits
remained constant during the pandemic. Educators can be confident
that their efforts to identify relevant, synoptic web resources are
still accessed even in challenging times.
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Providing AC2Tionable Feedback Improves Resident
and Fellow Satisfaction

Personal Protective Equipment Compliance: A Quality
Improvement Initiative

Deborah Simpson, Jacob L. Bidwell, Tricia La Fratta, Will
Lehmann, David Hamel, Nicole P. Salvo, William MacDonald,
Aboud Affi, M. Eyman Mortada, Colleen Nichols

Hilary Brown, Lizabeth Copre, Catherine Larson, Stephanie
Spacone-Perez, Laura Albanese, Sandra Weitzner, Mitali
Shah, Varsha P. Gharpure

Family Medicine and Academic Affairs, Aurora Sinai Medical
Center; Aurora Graduate Medical Education; Aurora
UW Medical Group; Family Medicine, Aurora St. Luke’s
Medical Center; Internal Medicine, Aurora Sinai Medical
Center; Obstetrics and Gynecology, Aurora Sinai Medical
Center; Radiology, Aurora St. Luke’s Medical Center;
Gastroenterology, Aurora Sinai Medical Center; Aurora
Cardiovascular Services, Aurora St. Luke’s Medical Center

Chicago Medical School; Advocate Children's Hospital

Background: Feedback is an essential component of the learning
process and is a required element for graduate medical education
program accreditation. Yet, it is often among the lowest-rated items
on education/teaching evaluations, is stressful for learners/teachers
alike, and is not actionable. To be actionable, feedback must
include current performance (omission/commission, deficient/
error), the desired goal performance (the gap), and a stepwise
approach to bridging that performance gap with strategies and
resources. Unfortunately, one or more of these elements is often
omitted, rendering most feedback unactionable.
Purpose: To educate learners and teachers to seek/provide
actionable feedback and determine if residents’ and fellows’
feedback ratings improve.
Methods: Over a 2-year period, faculty and trainees in
Accreditation Council on Graduate Medical Education
(ACGME)-approved residency/fellowship programs in our
sponsoring institution were invited to attend a 45-minute
actionable feedback session. The session was typically
incorporated into an established training program venue. The
core elements of actionable feedback were highlighted from both
a faculty and learner perspective using AC2T model: “A” = Ask
for feedback/Answer focused on specific performance gap; “C” =
Clarify if any actionable feedback elements were omitted; “C” =
Consider what steps you will take/Coach to support learning and
growth; “T” = say Thanks, as feedback is a dynamic relationship.
Sessions included feedback vignettes framed around specialtyspecific milestones to provide practice opportunities. Participant
pairs were given 90 seconds to complete the feedback interaction,
followed by a debriefing. ACGME-administered survey results
over 4 years were examined for the 2 years prior to AC2T and the
2 years of AC2T implementation.
Results: In each of the 2 years prior to AC2T implementation, our
ACGME mean rating on the item “satisfied with feedback” was
significantly below the national mean by 0.4 (5-point scale from
“extremely satisfied” to “not at all satisfied”). Response rate was
>98%: 139 of 141 for 2017; 163 of 167 for 2018). After AC2T
education in year 1, feedback item ratings improved to 0.20 below
national mean (response rate: 99% [168 of 170]); in year 2, ratings
reached the national mean (response rate: 85% during pandemic
[152 of 179]).
Conclusion: Focusing learner and faculty development on key
elements of actionable feedback is associated with dramatic
improvement in feedback ratings.

Background: Provider and patient safety is dependent on accurate
donning and doffing of personal protective equipment (PPE).
Studies prior to the COVID-19 pandemic have reported poor
adherence to PPE use, with higher risk of contamination during
doffing. Prepandemic audits at the pediatric general ward and
intensive care unit of Advocate Children’s Hospital (Park Ridge,
IL) showed varying compliance each month (88%–100%) with
donning. Doffing historically was never monitored. The COVID-19
pandemic has heightened the importance of donning and doffing
while making the process more complex due to need for additional
equipment and reuse of supplies.
Purpose: To identify and ameliorate modifiable individual and
system factors through process standardization and education to
achieve 100% compliance with PPE use.
Methods: The local institutional review board approved this
multidisciplinary quality improvement initiative. We used an
anonymous online survey (REDCap) and bedside audits to assess
baseline compliance and opportunities for intervention.
Results: 86 providers (27 physicians/advance practice providers,
38 nurses, 20 respiratory therapist, and 1 ancillary services)
returned the survey. Electronic communication from leadership
(63%) and an online COVID-19 toolkit (56%) were reported to
be major sources of information, while 13% had participated in
in-situ simulation. Only 20% reported to be very confident of their
own donning/doffing skills, while 29% were somewhat confident.
About 30% of team members self-reported errors/contamination
during donning or doffing; reasons were identified as lack of
knowledge of the current processes due to frequent changes in
recommendations (74%), lack of supplies consolidated in one
location (89%), distraction from phone calls/conversation (88%),
patient deterioration (66%), and PPE fatigue (33%). Baseline audit
revealed use of appropriate PPE by most providers, but the process
was often completed out of order or incorrectly.
Conclusion: We identified a need for additional education and
readily available supplies. Videos showing proper donning and
doffing technique, in-person validation of said technique, and justin-time review for team members are educational interventions to
be implemented. Custom-designed, dedicated PPE carts are placed
at the bedside for short-term storage and easy access to equipment.
A postintervention survey and audit will be completed to assess the
effectiveness of these interventions and identify future opportunities.
Evaluating the Pediatric Transitional Care Management
Visit at Aurora Sinai Family Care Center
Mary M. Dunkin, Fabiana Kotovicz, Alonzo Jalan, Jessica
J. F. Kram
Family Medicine, Aurora St. Luke’s Medical Center; Aurora
UW Medical Group; Center for Urban Population Health
Background: The U.S. Centers for Medicare & Medicaid Services
offers payment to outpatient primary care facilities to provide
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transitional care management (TCM) visits. The visit serves as a
handoff of patients from the acute inpatient setting to the outpatient
ambulatory environment, allowing succinct follow-up on medical
management. However, creating a thorough workflow and protocol
to establish TCM visits can be challenging, especially when
patients are mostly discharged from hospital facilities that are not
a part of one’s health system.
Purpose: To assess the current pediatric TCM workflow at an
academic primary care clinic, as well as missed opportunities
for pediatric hospital discharge follow-up and appropriate TCM
reimbursement.
Methods: The current pediatric TCM workflow was obtained
via informal interviews with care-coordinating staff members of
Aurora Family Care Center (Milwaukee, WI). A retrospective
chart review was performed for clinic patients, 3 days–18 years of
age, who were hospitalized during January–December 2019 and
who were discharged from any community hospital to outpatient
follow-up at Aurora Family Care Center. It was determined whether
TCM visits were performed following their hospital discharge.
Basic descriptive statistics and Mann-Whitney tests for continuous
analyses were used as appropriate. For outpatient visits not meeting
TCM criteria for billing, loss of reimbursement was calculated per
patient’s medical complexity at the time of their hospital discharge.
Results: Of the 46 patients who met inclusion criteria, mean age
was 7.3 years, mean hospital stay was 4.7 days, and 60.9% were
male. The two most common discharge diagnoses were respiratory
(24%) and surgical (24%). Overall, 22% (n=10) of pediatric
patients received a follow-up visit after discharge. However, only
50% (n=5) of the hospital discharge visits met criteria for TCM
billing. There were no statistically significant differences in whether
a TCM visit was performed based on median length of stay (2.5
vs 3 days; P=0.82). However, there was a statistically significant
difference based on age (0.2 vs 7.4 years; P=0.01). Reimbursement
for those who met TCM criteria was $963.44. The total estimated
potential TCM reimbursement for patients not meeting criteria
and who did not have a hospital follow-up was $7805.19.
Conclusion: Team-based TCM services are designed to allow
appropriate medical follow-up for recently discharged patients. Our
primary care clinics have room to implement a more standardized
and effective pediatric TCM process.
Assessing Comfortability and Knowledge of LGBTQ
Health in Family Medicine Residency Program
Steven Wipijewski, Jessica O’Brien
Family Medicine, Aurora St. Luke’s Medical Center
Background: The LGBTQ community experiences health
disparities, including higher mental health concerns and lower
likelihood to receive recommended preventive care. A contributing
factor to these disparities is a lack of physician comfort and
education on LGBTQ health.
Purpose: To assess primary care residents’ and attendings’ medical
knowledge and comfort of LGBTQ health issues before and after
formal education.
Methods: A pretest survey was emailed to residents and faculty
at the Aurora St. Luke’s Medical Center (Milwaukee, WI) family
medicine residency program. Questions included self-reported
knowledge and comfort of taking care of LGBTQ patients,
terminology, Centers for Disease Control and Prevention and U.S.
Preventive Services Task Force screening guidelines, and gender-
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affirming treatment options. After completion of the pretest survey,
two 15-minute lectures were provided during resident-faculty
meetings. After completion of the second lecture, a posttest survey
was emailed to residents and faculty.
Results: Pretest (n=34) and posttest (n=20) responses were
compared using chi-squared tests and Fisher’s exact test for
categorical variables and t tests for continuous variables. While
respondents reported improvement in knowledge (43.4% pretest
vs 53.1% posttest) and comfort (52.0% pretest vs 62.0% posttest)
after the lecture series, results were not statistically significant
(P=0.161 and P=0.191, respectively). There were no statistically
significant differences between pretest and posttest scores on
LGBTQ health questions.
Conclusion: While self-reported knowledge and comfort scores
improved after receiving lectures on LGBTQ health, results were
not statistically significant. Interpretation of the data was limited
due to fewer respondents on the posttest as well as having different
respondents when comparing pretest and posttest identifiers. It is
also unclear what percentage of residents and attendings were able
to attend either or both lecture series and whether more or longer
educational sessions would have increased medical knowledge and
comfort further. Addressing barriers to physician attendance and
completion of surveys could improve the study.
Gabapentin for Prophylaxis of Alcohol Withdrawal
Caroline Kruszecki, Tyler Cooper, Poorvi Shah
Pharmacy, Advocate Christ Medical Center;
Medicine, Advocate Christ Medical Center

Internal

Background: Limited information is available on the use of
pharmacological agents for alcohol withdrawal prophylaxis.
Current literature for benzodiazepines has been reported; however,
the role of gabapentin as a prophylactic agent has yet to be
determined.
Purpose: To evaluate the efficacy of gabapentin to prevent disease
progression in patients at high risk of developing severe alcohol
withdrawal.
Methods: This retrospective cohort study was approved by the
institutional review board and used electronic medical records
to identify patients who had Clinical Institute Withdrawal
Assessment (CIWA) scores monitored during inpatient stay.
Patients were included if their initial CIWA scores were <8 on
admission, indicating that they were not experiencing active
withdrawal symptoms. Patients who either experienced acute
alcohol withdrawal symptoms on admission as defined by a CIWA
score of >8 or were admitted for primary treatment of alcohol
withdrawal or dependence were excluded. The intervention
group consisted of patients who received gabapentin prior to a
reported CIWA score of >8, while the control group consisted of
those who did not. The following baseline characteristics were
collected: age, sex, weight, serum creatinine, liver function tests,
and history of alcohol withdrawal seizures or delirium tremens.
Primary objective of this study was to compare the number
of asymptomatic patients who progressed to severe alcohol
withdrawal (defined as 2 CIWA scores of >15 within an 8-hour
time period) when given gabapentin prophylaxis to those who
were not given gabapentin prophylaxis. Secondary endpoints
included medication use and duration (benzodiazepines,
antipsychotics, phenobarbital, propofol, and alpha-2 agonists),
CIWA scores, need for intensive care unit (ICU) admission,
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incidence of mechanical ventilation, ICU and hospital length of
stay, rates of complications, and select adverse effects.
Results: There were no differences in progression to severe
withdrawal, hospital length of stay, need for rescue medications,
benzodiazepine requirements, or adverse effects between patients
who received gabapentin for alcohol withdrawal prophylaxis and
those who did not. Median ICU length of stay was shorter among
patients who received gabapentin, with 300 mg every 8 hours the
most commonly observed gabapentin dosing regimen.
Conclusion: Larger prospective studies evaluating gabapentin
prophylaxis in high-risk patients are warranted. The lack of
observed differences in our study may be attributed to the small
sample size and the combination of low- and high-risk patients.
Demographics, Treatment, and Survival for Patients
Diagnosed With Pancreatic Cancer, 2010–2016
Maharaj Singh, Michelle Simpson
Advocate Aurora Research Institute; Ed Howe Center for
Research, Aurora Sinai Medical Center
Background: Incidence of and deaths caused by pancreatic cancer
have increased over recent years despite improvements in mortality
rate in other cancer types. Pancreatic cancer is a predominantly
asymptomatic cancer, very difficult to detect, with diagnosis late in
the disease. It is among the most lethal cancers.
Purpose: To describe the demographics among those who were
diagnosed with pancreatic cancer, evaluate incidence, mortality,
overall survival, and percent survival after 1, 2, and 5 years for
patients diagnosed with pancreatic cancer.
Methods: Data from the National Cancer Database for 2010–2016
was used for this study. We identified 384,753 patients diagnosed
with pancreatic cancer. In this study population, patients with
missing mortality (dead, alive) were excluded from the study
sample. Descriptive statistics and Cox regression were used to
analyze the data.
Results: Overall, the study cohort was 49% female, 79% nonHispanic White (NHW), 12% non-Hispanic Black (NHB), 5%
Hispanic, and 3% defined as “Other” race (Asians and Pacific
Islanders). Cox proportional hazard regression analysis showed
that female (hazard ratio: 0.95, 95% CI: 0.94–0.96) vs male sex,
Hispanic (0.96, 0.95–0.97), NHB (0.94, 0.93–0.95), and Other
(0.88, 0.87–0.89) vs NHW race/ethnicity, lower-medium (0.96,
0.95–0.97), medium (0.94, 0.93–0.95), and high (0.88, 0.87–0.89)
vs low patient income category, residence in metro (0.99, 0.98–
1.00) vs urban areas, living in the U.S. Eastern (0.96, 0.95–0.96)
and Western (0.99, 0.98–1.00) vs Central region, and having
government (0.90, 0.88–0.92) or private (0.84, 0.82–0.59) vs no
insurance all had lower hazards for mortality. Similarly, patients
who received treatment such as surgery (0.29, 0.29–0.30), radiation
(0.85, 0.84–0.86), chemotherapy (0.69, 0.69–0.70), immunotherapy
(0.76, 0.72–0.81), or hormonal therapy (0.50, 0.47–0.54) had lower
hazards for mortality, as did patients with higher Charlson-Dayo
score (1 vs 0: 1.13, 1.12–1.14; 2 vs 0: 1.27, 1.25–1.29; ≥3 vs 0:
1.48, 1.14–1.52). Also, 1-year increment in age increased risk of
dying by 1%–2% (1.01, 1.01–1.02).
Conclusion: Female, Hispanic, Asian and Pacific Islander, and
younger patients had better survival. Patients with insurance
(government or private) and patients who underwent treatment
had higher survival probability. Nationally, 5-year survival has
improved from 6% in 2004 to 13% in 2014.
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Review of Abametapir as a New Treatment for Head Lice*
Alexander D. Woods, Caroline L. Porter, Steven R. Feldman
Center for Dermatology Research, Wake Forest School of
Medicine
Background: Head lice, or Pediculus humanus capitis, is a
common yet difficult to treat ectoparasite. It has traditionally been
treated with over-the-counter synergized pyrethrin or pyrethroids
(permethrin); however, widespread resistance has led to the need
for novel pediculicides, such as abametapir 0.74% (Xeglyze).
Purpose: To review the pharmacology, safety, efficacy, and
clinical importance of abametapir.
Methods: A systematic review of the MEDLINE and Embase
databases was conducted for the terms “abametapir,” “Xeglyze,”
or “Ha44.” All relevant articles prior to December 2020 were
included.
Results: Abametapir works through chelating heavy metal
ions and inhibiting metalloproteinases critical to louse ova
development, hatching, and adult survival. A phase 2 trial using
an ex-vivo approach validated the direct ovicidal activity of
abametapir, inhibiting 100% of treated louse eggs from hatching
compared to 64% in the vehicle-treated group. With comparison
to untreated controls, the absolute hatch rate reduction was 92.2%
in abametapir-treated and 42.3% in vehicle-treated louse eggs
(P<0.001). Two identical phase 3 clinical trials conducted in 704
patients with head lice infestations showed subjects treated with
a single 10-minute application of abametapir had a significantly
greater proportion of treatment success (ie, lice-free through 14
days) compared to vehicle-treated subjects with 81.1% success vs
50.9% (P=0.001) and 81.8% vs 47.2% (P<0.001) in each respective
trial. Abametapir was well tolerated, with mild scalp erythema,
rash, skin burning sensation, and contact dermatitis being the most
commonly experienced adverse effects.
Conclusion: Abametapir 0.74% was recently approved by
the U.S. Food and Drug Administration for single-application
treatment for head lice in patients 6 months of age and older.
Its direct ovicidal and lousicidal activity is effective in treating
head lice infestations with one application. In the face of growing
resistance to current pediculicides, abametapir offers a safe and
effective new treatment.
*Data republished from Woods AD, Porter CL, Feldman SR.
Abametapir for the treatment of head lice: a drug review. Ann
Pharmacother. 2021 Jun 22 [Epub ahead of print]; with permission
from SAGE Publishing.
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